Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- SGH +10.3%, CTAS +3.3%
M&A news:
- RXDX +72.7%, (Ignyta agrees to be acquired by Roche (RHHBY) for $27.00/share in cash, or approximately $1.7 bln)
Other news:
- LJPC + 11.3% (La Jolla Pharm announced FDA has approved Giapreza),
- NXTD +7.9% (Continued strength),
- MTL +6.4% (Still checking),
- RDHL +4.2% (announces initiation of phase iia study with ABC294640),
- AA +2.1% (Announced decisions regarding smelting assets in the United States and Italy),
- RAD +2.0% (Still checking).
Analyst comments:
- SGH +10.1% (Earnings, Stifel raises tgt to $47).